Specifically, NAD rejected Willows argument based on physician prescribing practices, stating that an experts conclusory statement or action is of little value and that expert opinions are most reliable when coupled with competent and reliable evidence demonstrating scientific consensus on an issue. NAD also found that studies referenced by Willow concerning the effectiveness of its products for weight loss only involved FDA-approved GLP-1 products and were insufficient to validate claims for compounded alternatives that differ in active pharmaceutical ingredient, formulation or method of administration. Therefore, NAD concluded that Willow did not establish a reasonable basis for its claims and recommended that Willow discontinue or modify its advertising
For some patients, longer-term use may be necessary, but this should be under close medical supervision.
Get a 90-day supply A 90-day supply may be cheaper per dose than a one-month or two-month supply, and it can also reduce the number of trips to your pharmacy
It is also explored for its ability to accelerate recovery following physical stress or injury, making it relevant in performance-focused studies
The agencies' actions against Seasilver USA, Inc.
How to tell if your tirzepatide has gone bad Visual inspection is your first line of defense, but it has significant limitations
